These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 19724022)

  • 1. Fetal liver X receptor activation acutely induces lipogenesis but does not affect plasma lipid response to a high-fat diet in adult mice.
    van Straten EM; van Meer H; Huijkman NC; van Dijk TH; Baller JF; Verkade HJ; Kuipers F; Plösch T
    Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1171-8. PubMed ID: 19724022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systems biology approach to the hepatic role of the oxysterol receptor LXR in the regulation of lipogenesis highlights a cross-talk with PPARα.
    Ducheix S; Podechard N; Lasserre F; Polizzi A; Pommier A; Murzilli S; Di Lisio C; D'Amore S; Bertrand-Michel J; Montagner A; Pineau T; Loiseau N; Lobaccaro JM; Martin PG; Guillou H
    Biochimie; 2013 Mar; 95(3):556-67. PubMed ID: 23063693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological activation of LXR in utero directly influences ABC transporter expression and function in mice but does not affect adult cholesterol metabolism.
    van Straten EM; Huijkman NC; Baller JF; Kuipers F; Plösch T
    Am J Physiol Endocrinol Metab; 2008 Dec; 295(6):E1341-8. PubMed ID: 18840761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in LXR signaling influence early-pregnancy lipogenesis and protect against dysregulated fetoplacental lipid homeostasis.
    Nikolova V; Papacleovoulou G; Bellafante E; Borges Manna L; Jansen E; Baron S; Abu-Hayyeh S; Parker M; Williamson C
    Am J Physiol Endocrinol Metab; 2017 Oct; 313(4):E463-E472. PubMed ID: 28420650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
    Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.
    Gao M; Bu L; Ma Y; Liu D
    PLoS One; 2013; 8(6):e65641. PubMed ID: 23762402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholic acid inhibits liver X receptor α-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE.
    Lee JM; Gang GT; Kim DK; Kim YD; Koo SH; Lee CH; Choi HS
    J Biol Chem; 2014 Jan; 289(2):1079-91. PubMed ID: 24265317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-sensitizing effect of LXR agonist T0901317 in high-fat fed rats is associated with restored muscle GLUT4 expression and insulin-stimulated AS160 phosphorylation.
    Baranowski M; Zabielski P; Błachnio-Zabielska AU; Harasim E; Chabowski A; Górski J
    Cell Physiol Biochem; 2014; 33(4):1047-57. PubMed ID: 24732673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systems biology approach reveals the physiological origin of hepatic steatosis induced by liver X receptor activation.
    Hijmans BS; Tiemann CA; Grefhorst A; Boesjes M; van Dijk TH; Tietge UJ; Kuipers F; van Riel NA; Groen AK; Oosterveer MH
    FASEB J; 2015 Apr; 29(4):1153-64. PubMed ID: 25477282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. n-3 fatty acids ameliorate hepatic steatosis and dysfunction after LXR agonist ingestion in mice.
    Jung UJ; Millman PN; Tall AR; Deckelbaum RJ
    Biochim Biophys Acta; 2011 Sep; 1811(9):491-7. PubMed ID: 21704188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
    Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
    Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid hormone-responsive SPOT 14 homolog promotes hepatic lipogenesis, and its expression is regulated by liver X receptor α through a sterol regulatory element-binding protein 1c-dependent mechanism in mice.
    Wu J; Wang C; Li S; Li S; Wang W; Li J; Chi Y; Yang H; Kong X; Zhou Y; Dong C; Wang F; Xu G; Yang J; Gustafsson JÅ; Guan Y
    Hepatology; 2013 Aug; 58(2):617-28. PubMed ID: 23348573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
    Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
    Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of liver X receptors attenuates endotoxin-induced liver injury in mice with nonalcoholic fatty liver disease.
    Liu Y; Han X; Bian Z; Peng Y; You Z; Wang Q; Chen X; Qiu D; Ma X
    Dig Dis Sci; 2012 Feb; 57(2):390-8. PubMed ID: 21948338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resveratrol suppresses T0901317-induced hepatic fat accumulation in mice.
    Gao M; Liu D
    AAPS J; 2013 Jul; 15(3):744-52. PubMed ID: 23591747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver X receptor agonist T0901317 enhanced peroxisome proliferator-activated receptor-delta expression and fatty acid oxidation in rat skeletal muscle.
    Baranowski M; Blachnio-Zabielska AU; Zabielski P; Harasim E; Harasiuk D; Chabowski A; Gorski J
    J Physiol Pharmacol; 2013 Jun; 64(3):289-97. PubMed ID: 23959725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding.
    Kay HY; Kim WD; Hwang SJ; Choi HS; Gilroy RK; Wan YJ; Kim SG
    Antioxid Redox Signal; 2011 Oct; 15(8):2135-46. PubMed ID: 21504366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCAAT/enhancer binding protein β deletion increases mitochondrial function and protects mice from LXR-induced hepatic steatosis.
    Rahman SM; Choudhury M; Janssen RC; Baquero KC; Miyazaki M; Friedman JE
    Biochem Biophys Res Commun; 2013 Jan; 430(1):336-9. PubMed ID: 23159614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of insulin resistance and adiponectin signaling in adipose tissue by liver X receptor activation highlights a cross-talk with PPARγ.
    Zheng F; Zhang S; Lu W; Wu F; Yin X; Yu D; Pan Q; Li H
    PLoS One; 2014; 9(6):e101269. PubMed ID: 24972069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver X receptor agonists augment human islet function through activation of anaplerotic pathways and glycerolipid/free fatty acid cycling.
    Ogihara T; Chuang JC; Vestermark GL; Garmey JC; Ketchum RJ; Huang X; Brayman KL; Thorner MO; Repa JJ; Mirmira RG; Evans-Molina C
    J Biol Chem; 2010 Feb; 285(8):5392-404. PubMed ID: 20007976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.